MA56386A - Polythérapie comprenant de l'acétyl-leucine et du miglustat - Google Patents

Polythérapie comprenant de l'acétyl-leucine et du miglustat

Info

Publication number
MA56386A
MA56386A MA056386A MA56386A MA56386A MA 56386 A MA56386 A MA 56386A MA 056386 A MA056386 A MA 056386A MA 56386 A MA56386 A MA 56386A MA 56386 A MA56386 A MA 56386A
Authority
MA
Morocco
Prior art keywords
polytherapy
miglustat
leucine
including acetyl
acetyl
Prior art date
Application number
MA056386A
Other languages
English (en)
Other versions
MA56386B1 (fr
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA56386A publication Critical patent/MA56386A/fr
Publication of MA56386B1 publication Critical patent/MA56386B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA56386A 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale MA56386B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962868383P 2019-06-28 2019-06-28
US201962931003P 2019-11-05 2019-11-05
PCT/IB2020/056096 WO2020261230A1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat
EP20736444.9A EP3989962B1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale

Publications (2)

Publication Number Publication Date
MA56386A true MA56386A (fr) 2022-05-04
MA56386B1 MA56386B1 (fr) 2025-10-31

Family

ID=71452519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56386A MA56386B1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale

Country Status (16)

Country Link
US (1) US20220362189A1 (fr)
EP (2) EP4650003A3 (fr)
DK (1) DK3989962T3 (fr)
ES (1) ES3048174T3 (fr)
FI (1) FI3989962T3 (fr)
HR (1) HRP20251256T1 (fr)
HU (1) HUE073420T2 (fr)
LT (1) LT3989962T (fr)
MA (1) MA56386B1 (fr)
MD (1) MD3989962T2 (fr)
PL (1) PL3989962T3 (fr)
PT (1) PT3989962T (fr)
RS (1) RS67283B1 (fr)
SI (1) SI3989962T1 (fr)
SM (1) SMT202500369T1 (fr)
WO (1) WO2020261230A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
BR112021010923A2 (pt) * 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
CN118409027B (zh) * 2024-07-02 2024-09-10 成都市食品检验研究院 一种食品中1-脱氧野尻霉素的含量检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588130B1 (fr) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Administration au snc d'agents thérapeutiques
KR102467953B1 (ko) * 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Also Published As

Publication number Publication date
RS67283B1 (sr) 2025-11-28
DK3989962T3 (da) 2025-10-13
ES3048174T3 (en) 2025-12-09
MD3989962T2 (ro) 2025-12-31
US20220362189A1 (en) 2022-11-17
EP3989962A1 (fr) 2022-05-04
EP3989962B1 (fr) 2025-08-27
EP4650003A3 (fr) 2026-01-21
SI3989962T1 (sl) 2025-11-28
PL3989962T3 (pl) 2025-11-17
WO2020261230A1 (fr) 2020-12-30
PT3989962T (pt) 2025-10-09
FI3989962T3 (fi) 2025-10-08
MA56386B1 (fr) 2025-10-31
HUE073420T2 (hu) 2026-01-28
SMT202500369T1 (it) 2025-11-10
HRP20251256T1 (hr) 2025-12-05
EP4650003A2 (fr) 2025-11-19
LT3989962T (lt) 2025-10-10

Similar Documents

Publication Publication Date Title
EP3773939A4 (fr) Structure d'exercice universelle polyvalente
EP3934861A4 (fr) Robot d'inspection
EP3926701A4 (fr) Panneau d'affichage
EP3735685A4 (fr) Panneau d'affichage
EP3750149C0 (fr) Panneau d'affichage
EP3798719A4 (fr) Panneau d'affichage
EP3849655A4 (fr) Fabrication et conception d'électrode
UA42369S (uk) Комп'ютер
UA42295S (uk) Комп'ютер
EP3756061A4 (fr) Mécanismes de levage d'affichage
EP3816311A4 (fr) Tuyau d'acier et tôle d'acier
EP3813861A4 (fr) Polypeptides associés à l'héparine et leurs utilisations
EP3982415A4 (fr) Panneau d'affichage
EP3875624A4 (fr) Tôle d'acier inoxydable austénitique
DK3979827T3 (da) Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose
EP3705768A4 (fr) Emboîture et raccord de tuyau comprenant celle-ci
EP3914362C0 (fr) Machine d'exercice
EP3790683A4 (fr) Ensemble d'entraînement
EP3966321A4 (fr) Ligases de protéine spécifiques à l'asx et leurs utilisations
MA51708A (fr) Identification d'applications avec l'apprentissage machine
PT4011898T (pt) Derivado de 3-hidroxi-5-pregnano-20-ona e sua utilização
EP4036586A4 (fr) Récipient et kit d'inspection
EP3746191A4 (fr) Équipement d'entraînement avec des poids modifié
EP3815846A4 (fr) Machine d'entraînement
EP3601572A4 (fr) Construction d'expression de protéine et procédés associés